Rigor Reviewed

Rigor-Reviewed Manuscript

A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.

Name: Αlpha¹ Rigor Record — A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.
Item: A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.
Rating: 59
Author: Αlpha¹

Lucinde RK, Gathuri H, Mwaniki P, Orindi B, Otieno EO, Mwakio S, Mulemi L, Isaaka L, Shangala J, Saisi M, Isinde E, Oginga IN, Wachira AW, Manuthu E, Kariuki H, Asaava P, Nyikuli J, Wekesa C, Otedo A, Bosire H, Okoth SB, Ongalo W, Mukabi DM, Lusamba W, Muthui B, Adembesa I, Mithi C, Sood M, Aliyan NA, Gituma B, Matiko MG, Omondi CA, Ombajo LA, Kirui N, Ochola L, Abdi AI, Kagucia EW, English M, Hamaluba M, Ochola-Oyier I, Kamuya D, Bejon P, Barasa E, Agweyu A, Akech S, Etyang AO

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.5★ (Critical), 0 critical, 6 high issues for “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Ethics/consent reporting incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This pragmatic open-label RCT of adjunctive glucocorticoids for CAP in Kenya is well-designed (central randomization, pre-specified power, verified statistical analyses) and transparent in most reporting dimensions. Its main weaknesses are the absence of a data-availability statement, incomplete identification of key resources (drug manufacturers, statistical software), and a missing explicit regulatory-compliance statement, plus an unreconciled baseline imbalance claim versus Table 1.

Two independent reviewer runs (same model) converged on all eight dimension statuses and the overall score; minor divergence on the open-label justification and the chronic-illness table consistency did not change any status. The statistics verification recomputed only 2 of the paper's tests (limited coverage); the citation check found no retracted or unlocatable references (29 checked).

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions5 pass · 1 warn · 2 fail

The background cites prior trials and systematic reviews on glucocorticoids for CAP, notes the higher mortality in sub-Saharan Africa, and identifies gaps such as exclusion of HIV/TB patients, older age, and ICU focus. The rationale for the trial is logically linked to these gaps.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior studies, acknowledging their limitations, and providing a rationale for the trial in low-resource settings.

Evidence

direct quote[Background, paragraph 2]

“Data from two recently published trials and systematic reviews of adjunctive hydrocortisone in CAP requiring intensive care unit (ICU) admission – , indicate reduced mortality among these patients.”